ArticleTranslational cancer research2025
Liriopesides B inhibits proliferation and metastasis and induces apoptosis of oral squamous cell carcinoma via the PI3K/Akt/mTOR signaling pathway.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Liriopesides B (LPB), a steroidal saponin derived from Liriope spicata, demonstrates potent anti-tumor activity across multiple malignancies. Nevertheless, its influence on oral squamous cell carcinoma (OSCC) has not been investigated. This study aims to evaluate the anti-OSCC properties of LPB and elucidate the underlying mechanisms. Methods: Proliferation of OSCC cells treated with LPB was evaluated via Cell Counting Kit-8 (CCK-8) and colony formation assays. Cell migration, invasion, and apoptosis were analyzed, along with measuring related gene expression utilizing quantitative reverse transcription polymerase chain reaction (qRT-PCR). Transcriptomic analysis of LPB-treated cells was performed, and protein levels within the PI3K/Akt/mTOR cascade were examined by Western blotting. Results: LPB suppressed OSCC cell growth, colony formation, motility, and invasiveness while promoting apoptosis. High-throughput sequencing suggested that the PI3K/Akt cascade is a potential target of LPB in OSCC. Treatment with LPB markedly suppressed key protein levels within the PI3K/Akt/mTOR cascade. In xenograft models, LPB treatment led to considerable decreases in tumor volume and weight. Furthermore, mRNA levels of MMP-2/9 and proteins such as PI3K, Akt, p-mTOR, and S6 were markedly downregulated in LPB-treated tumors, while Bax and Bad expression were upregulated. No substantial variations in body weight, histological morphology, or organ function were observed between the control and LPB-treated cohorts. Conclusions: LPB exerts anti-OSCC properties by modulating the PI3K/Akt/mTOR cascade with minimal biological toxicity, highlighting its potential as a therapeutic agent for OSCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.